Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

NEW YORK, N.Y. – Drug giant Pfizer Inc. says its third-quarter profit fell 14 per cent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world’s top-selling drug.
The maker of pain reliever Lyrica says net income was $3.21 billion, or 43 cents per share. That was down from $3.74 billion, or 48 cents per share, a year earlier.
Excluding one-time items, earnings were 53 cents per share. Analysts expected 52 cents.
Revenue fell 16 per cent to $13.98 billion, below expectations for $14.66 billion.
Pfizer raised its 2012 profit forecast, to $1.30 to $1.38 per share, from $1.21 to $1.36 per share, but reduced the top end of its revenue forecast by $1 billion.
Pfizer’s stock fell 52 cents, or 2.1 per cent, to $24.35 in premarket trading.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.